Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 8 (5), 685-697
- https://doi.org/10.1158/2326-6066.cir-19-0467
Abstract
Epitopes derived from mutated cancer proteins elicit strong antitumor T-cell responses that correlate with clinical efficacy in a proportion of patients. However, it remains unclear whether the subcellular localization of mutated proteins influences the efficiency of T-cell priming. To address this question we compared the immunogenicity of NY-ESO-1 and OVA localized either in the cytosol or in mitochondria. We showed that tumors expressing mitochondrial-localized NY-ESO-1 and OVA proteins elicit significantly higher frequencies of antigen-specific CD8+ T cells in vivo. We also demonstrated that this stronger immune response is dependent on the mitochondrial location of the antigenic proteins, which contributes to their higher steady state amount, compared with cytosolic-localized proteins. Consistent with these findings, we showed that injection of mitochondria purified from B16 melanoma cells can protect mice from a challenge with B16 cells, but not with irrelevant tumors. Finally, we extended these findings to cancer patients by demonstrating the presence of T-cell responses specific for mutated mitochondrial-localized proteins. These findings highlight the utility of prioritizing epitopes derived from mitochondrial-localized mutated proteins as targets for cancer vaccination strategies.Keywords
Other Versions
Funding Information
- UK Research and Innovation | Medical Research Council (HIU)
- The Oxford Biomedical Research Centre (BRC)
- Cancer Research UK (C399/A2291)
This publication has 49 references indexed in Scilit:
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cellsBlood, 2012
- MPYS Is Required for IFN Response Factor 3 Activation and Type I IFN Production in the Response of Cultured Phagocytes to Bacterial Second Messengers Cyclic-di-AMP and Cyclic-di-GMPPublished by The American Association of Immunologists ,2011
- Absence of scavenger receptor A promotes dendritic cell‐mediated cross‐presentation of cell‐associated antigen and antitumor immune responseImmunology & Cell Biology, 2011
- Identification of a dendritic cell receptor that couples sensing of necrosis to immunityNature, 2009
- NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cellsBlood, 2008
- Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell ImmunityScience, 2008
- Generation of peptide–MHC class I complexes through UV-mediated ligand exchangeNature Protocols, 2006
- Molecular identification of a danger signal that alerts the immune system to dying cellsNature, 2003
- Epitope selection in major histocompatibility complex class I-mediated pathway is affected by the intracellular localization of an antigenEuropean Journal of Immunology, 1997